Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 3,096 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 3,096 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $50.13, for a total value of $155,202.48. Following the completion of the sale, the director now owns 279,787 shares in the company, valued at approximately $14,025,722.31. This represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pro-Dex Stock Up 1.2 %

Pro-Dex stock opened at $49.98 on Friday. The firm has a market cap of $162.98 million, a PE ratio of 24.87 and a beta of 0.68. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 2.58. Pro-Dex, Inc. has a twelve month low of $16.84 and a twelve month high of $59.60. The firm’s 50 day moving average price is $40.13 and its two-hundred day moving average price is $39.75.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. On average, research analysts predict that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com cut shares of Pro-Dex from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th.

Hedge Funds Weigh In On Pro-Dex

A number of hedge funds have recently made changes to their positions in PDEX. FMR LLC lifted its position in shares of Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after buying an additional 1,028 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Pro-Dex in the 4th quarter worth about $202,000. Trexquant Investment LP acquired a new stake in shares of Pro-Dex during the 4th quarter worth about $252,000. Integrated Quantitative Investments LLC bought a new position in Pro-Dex during the 4th quarter valued at about $254,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Pro-Dex in the fourth quarter valued at about $255,000. Institutional investors and hedge funds own 15.28% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.